Breast Cancer | Specialty

Evolving Treatment Landscape of R/R HER2+ mBC

April 22nd 2020

Payer Coverage of IV Versus Oral Therapy in mBC

April 22nd 2020

Compliance and Adherence to Therapy in mBC

April 22nd 2020

Advantages of Oral Taxanes in mBC

April 22nd 2020

Payer Coverage on Repeat Biopsy in mBC

April 22nd 2020

Payer Perspective of Coverage on Cancer Therapies

April 22nd 2020

SOLAR-1 Trial in Metastatic Breast Cancer

April 22nd 2020

Treatment After Progression on CDK 4/6i in mBC

April 22nd 2020

Expert Highlights Benefit of PARP Inhibitors in BRCA+ Breast Cancer and Potentially Beyond

April 18th 2020

Melinda L. Telli, MD, discusses the role of PARP inhibition in the treatment of patients with breast cancer who harbor the BRCA mutations and ongoing research efforts seeking to expand their use beyond this setting.

Dr. Graff on Genomic Risk Prediction in HR+/HER2- Breast Cancer

April 11th 2020

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.

A National Perspective on the Multidisciplinary Management of Breast Cancer Through the COVID-19 Pandemic

April 10th 2020

This OncLive® webinar will focus on the impact of COVID-19 in patients with breast cancer and the innovative ways in which treatment has evolved during this time. Join us on May 7, 2020 at 8 PM EDT.

Dr. Tolaney on Sequencing Questions in Breast Cancer

April 7th 2020

Sara M. Tolaney, MD, MPH, discusses remaining sequencing questions in breast cancer.

Evidence-Based Strategies Help Guide Need for ALND in Breast Cancer

April 5th 2020

Anees B. Chagpar, MD, outlines several strategies to minimize the use of ALND in patients with breast cancer.

Inclusion of Geriatric Populations in Breast Cancer Research Needed to Improve Care

April 3rd 2020

Enrique Soto Pérez de Celis, MD, MSc, discusses some of the challenges of treating geriatric patients with breast cancer, emerging treatment options for this patient population, and recommendations for treating older patients.

Dr. Kalinksy on pCR as a Surrogate Marker for EFS in TNBC

April 3rd 2020

Kevin Kalinsky, MD, MS, assistant professor of medicine, Division of Hematology and Oncology, NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses the use of pathologic complete response (pCR) rate as a surrogate marker for event-free survival (EFS) in triple-negative breast cancer (TNBC).

Dr. Lynce on Remaining Questions With PARP Inhibitors in Breast Cancer

April 2nd 2020

Filipa Lynce, MD, discusses remaining questions regarding the use of PARP inhibitors in breast cancer.

Dr. Dawar on Challenges With Neratinib in Metastatic HER2+ Breast Cancer

April 1st 2020

Richa Dawar, MD, discusses challenges with the use of neratinib in patients with metastatic HER2-positive breast cancer.

Dr. Jochelson on the Limitations of Mammography and Ultrasound in Screening for Breast Cancer

April 1st 2020

Maxine S. Jochelson, MD, discusses the limitations of mammography and ultrasound in screening patients for breast cancer.

Opening the Door for Novel Therapies in Triple-Negative Breast Cancer

March 31st 2020

During a recent OncLive Peer Exchange®, the expert panel focused on the development of immunotherapy and other notable successes based on recent presentations at the 2019 San Antonio Breast Cancer Symposium.

Dr. Vargas on the Utility of Sentinel Node Biopsy in Breast Cancer

March 31st 2020

Hernan Vargas, MD, FACS, a breast surgeon at Virginia Cancer Specialists, discusses the utility of sentinel lymph node biopsy in breast cancer.